Recombinant human IL-15 protein - Bioactive cytokine

Recombinant cytokine, source: CHO cells

ABOUT

Human IL-15 protein - Mammalian cell-expressed, tag-free, carrier-free

Recombinant human IL-15 is a high-quality and biologically active cytokine, validated using proprietary IL-15 reporter cells. This immunomodulating cytokine of the γc superfamily is produced in CHO cells to ensure protein glycosylation and bona fide 3D structure.

Recombinant human IL-15 can be used together with HEK-Blue™ IL-2/IL-15 cells, a cell line that detects human IL-15, for the screening of inhibitory molecules, such as Ordesekimab, a therapeutic monoclonal antibody targeting the IL-15 cytokine (see figures).

 

Key features

  • Each lot is validated using HEK-Blue™ IL-2/IL-15 cells
  • Endotoxin < 0.01 EU/µg
  • 0.22 µm sterile-filtered 

Applications

  • T cell and NK cell activation and propagation
  • IL-15 detection and quantification assays (positive control)
  • Screening and release assays for antibodies blocking IL-15 signaling
  • Screening and release assays for engineered IL-15 proteins

 

Interleukin 15 (IL-15) is an immunomodulating cytokine that is structurally and functionally related to IL-2. IL-15 promotes the ontogeny, activation, and survival of NK cells, NKT cells, T cells, and B cells. IL-15 also plays controversial roles in the development and progression of various hematological malignancies. Recombinant IL-15 can be used in combination with other cytokines like IL-2 or IL-7 to increase the efficiency of T and NK cell expansion and maturation in cell culture protocols.

More details

All InvivoGen products are for internal research use only, and not for human or veterinary use.

IL-15 signaling and biological functions
IL-15 signaling and biological functions

SPECIFICATIONS

Specifications

Source
CHO cells
Species
Human
Accession sequence

P40933

Protein size
114 a.a. (N49-S162)
Molecular weight
~ 13 kDa (SDS-PAGE)
International units (IU)

>107 IU/mg*

Carrier
Carrier-free
Tag
Tag-free
Purity
≥ 95% (SDS-PAGE)
Solubility

100 μg/ml in water

Formulation buffer

Phosphate buffer saline (pH 7.4), 5% saccharose

Appearance (form)
Lyophilized
Reconstitution buffer
Endotoxin-free water (provided)
Sterility

0.22 µm filtration

Endotoxin

The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK‑Blue™ TLR4 cells.

Applications

Cellular assays (tested), Cell culture (T cell and NK cell activation and expansion), ELISA

Quality control

Each lot is functionally tested and validated.

Additional information

*Please refer to the corresponding Certificate of Analysis (CoA) for the exact value.

CONTENTS

Contents

  • Product: 
    Recombinant human IL-15
  • Cat code: 
    rcyc-hil15
  • Quantity: 
    10 µg
Includes:

1.5 ml endotoxin-free water

Shipping & Storage

  • Shipping method:  Room temperature

    • Storage:

    • -20°C
    Stability: -20°C for up to 1 year

    Caution:

    • Avoid repeated freeze-thaw cycles

Details

Interleukin 15 Signaling

IL-15 and IL-2 are two closely related cytokines that belong to the IL-2 family and display important functions in the immune system [1]. They share the heterodimeric CD122 (IL-2Rβ)/CD132 (IL-2Rγ) receptor to deliver their signals within target cells. Their specificity of action is conferred by their α receptor chains, CD25 (IL-2Rα) and CD215 (IL-15Rα). The binding of IL-15 and IL-2 to their heterodimeric or heterotrimeric receptors activates a signaling cascade through tyrosine kinases of the Janus family (JAK1 and JAK3) and signal transducer and transcription activator 5 (STAT5) [1]. This results in the subsequent induction of proliferation and anti-apoptotic transcriptional program and can, if uncontrolled, potentially lead to malignant transformation [2]. IL-15 can sustain chronic inflammation, autoimmunity, and uncontrolled T cell proliferation, leading to T cell lymphoma development [1].

 

IL-15 therapeutic targeting

The multi-faceted nature of IL-15, its anti-tumorigenic abilities as a booster of the immune response, and its pathogenic function as a driver of malignant cell proliferation harbors a high potential as a therapeutic tool [1]. Numerous IL-15-enhancing approaches have been used to treat different cancers, including leukemias and lymphomas, exploiting the main function of the cytokine to potentiate NK and T cell responses and unleash immune-mediated cancer eradication. On the other hand, agents that inhibit IL-15 are also being extensively tested as therapeutic approaches against cancer, such as soluble IL-15Rα, antibodies against IL-15 or components of the heterotrimeric receptor, and steric antagonists of the receptor in the form of a modified IL-2 [1]. Moreover, the IL-15 cytokine, together with IL-2 and IL-7, is currently under investigation for application in ex vivo T cell expansion. These cytokines are used in different concentrations and combinations to improve cell viability, proliferation, and differentiation in CAR T cell culture [2-3]. 

 

References:

1. Sindaco P, et al., 2023. The role of interleukin-15 in the development and treatment of hematological malignancies. Front Immunol.14:1141208.
2. Sudarsanam H, et al., 2022. Influence of Culture Conditions on Ex Vivo Expansion of T Lymphocytes and Their Function for Therapy: Current Insights and Open Questions. Front Bioeng Biotechnol.;10:886637
3. Chamucero-Millares JA, et al., 2021. Usefulness of IL-21, IL-7, and IL-15 conditioned media for expansion of antigen-specific CD8+ T cells from healthy donor-PBMCs suitable for immunotherapy. Cell Immunol.;360

You may also need

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?